1. Introduction {#s0005}
===============

Salivary excretion of some drugs has been reported previously as a good indicator for drug bioavailability, therapeutic drug monitoring, pharmacokinetics and also drug abuse. Saliva sampling offers simple, non-invasive and cheap method as compared with plasma sampling with no contamination risk ([@b0015], [@b0050]). The rules of drug protein binding and membrane permeability on salivary excretion were previously investigated for several drugs, where a Salivary Excretion Classification System (SECS) was proposed as shown in [Table 1](#t0005){ref-type="table"} ([@b0020]). High intestinal permeability corresponds to fraction absorption *F~a~* \> 0.9 and high protein binding corresponds to low fraction unbound fu of \<0.1 ([@b0005], [@b0055]). According to SECS classification Class I drugs of high intestinal permeability and low protein binding, such as paracetamol, are subjected to salivary excretion. Class II drugs of low permeability and low protein binding, such as metformin, are subjected to salivary excretion since low permeability is counterbalanced by low protein binding. Class III drugs of high intestinal permeability and high protein binding, such as tolterodine, are subjected to salivary excretion since high protein binding is counterbalanced by high permeability. Class IV drugs of low intestinal permeability and high protein binding, such as montelukast, are not subjected to salivary excretion ([@b0020]).Table 1Salivary Excretion Classification System (SECS) according to drug permeability (*P*~eff~) and fraction unbound to plasma proteins (fu).ClassParameter*P*~eff~fuSalivary excretionClass IHighHighYesClass IILowHighYesClass IIIHighLowYesClass IVLowLowNo

Four pilot studies were previously done in our laboratory on SECS class I drugs: paracetamol and tolterodine, SECS class II drug: metformin and SECS class III drug: rosuvastatin. Results were promising and have demonstrated high saliva-plasma correlations with relatively higher variability in saliva parameters ([@b0025], [@b0030], [@b0035], [@b0040]).

2. Objective {#s0010}
============

The objective of this review was to further investigate the robustness of using non-invasive saliva sampling method instead of plasma sampling method as a surrogate for bioavailability and bioequivalence studies of SECS classes I, II and III drugs that are excreted in saliva.

3. Experimental {#s0015}
===============

Saliva BA/BE under fasted state, in 12--18 healthy human volunteers after signing informed consent, was compared to plasma pharmacokinetics in crossover or parallel design studies. Medical history, vital signs, physical examination, and laboratory safety test results showed no evidence of clinically significant deviation from normal medical condition as evaluated by the clinical investigator. The pilot bioavailability study was conducted as per the ICH, GCP, and Helsinki declaration guidelines after IRB of International Pharmaceutical Research Center and Jordan FDA approvals. Single oral doses of study drugs were administered after 10 h overnight fasting without dietary restrictions. Then resting saliva (without stimulation) and plasma samples were collected at specific time intervals up to 3--5 half lives. Thorough rinsing of the mouth was done after dosing to avoid contamination of saliva samples with any drug residues. Sensitive and accurate LC-MS/MS methods were developed and validated for the determination of study drugs in human plasma and saliva ([@b0025], [@b0030], [@b0035], [@b0040]).

4. Data analysis {#s0020}
================

4.1. Pharmacokinetic analysis {#s0025}
-----------------------------

Individual pharmacokinetic parameters for drug concentration in both saliva and plasma samples were calculated by non-compartmental analysis (NCA) using Kinetica program V5. Investigated pharmacokinetic parameters were area under the concentration curves to last collection time (AUC*~t~*), maximum measured concentration (*C*~max~) and time to maximum concentration (*T*~max~).

4.2. Dimensional and correlation analysis {#s0030}
-----------------------------------------

Saliva versus plasma concentration up to median *T*~max~ value of plasma data was correlated by linear regression using Microsoft Excel. On the other hand, dimensional analysis was done on individual bases. This offers an advantage of more clear comparisons since ratios are unit less. The following dimensionless ratios were calculated:AUC*~t~*^∗^ = saliva AUC*~t~*/plasma AUC*~t~T*~max~^∗^ = saliva *T*~max~/plasma *T*~max~*C*~max~^∗^ = saliva *C*~max~/plasma *C*~max~*C*^∗^ = saliva Concentration/plasma concentration = *C~s~*/*C~p~P*~eff~^∗^ = dimensionless effective permeability = (*R*·*P*~eff~)/*D*

where *D* is drug diffusivity as predicted by SimCYP.

4.3. Absorption kinetics {#s0035}
------------------------

Effective intestinal permeability (*P*~eff~) values were estimated by Nelder-Mead algorithm of Parameter Estimation module using SimCYP program ([@b0045]). Nelder-Mead method, which is also called downhill simplex, is a commonly used nonlinear optimization algorithm. This was done by searching for the best parameter values that produce plasma concentration that matches the actual plasma concentration at the same time. The objective function is the weighted sum of squared differences of observed and model predicted values. Polar surface area (PSA) was used first, using SimCYP, to predict initial estimate of *P*~eff~. Fraction absorption (Fa) was calculated according to equations below:Fa = 1 − e^−2An^An = *P*~eff~ · *t*~res~/*R*where An is the absorption number; *R* and *t*~res~ are radius, set at 1.75 cm, and mean residence time, set at 3 h, in the human small intestine respectively ([@b0060]).

5. Results and discussion {#s0040}
=========================

All reviewed drugs showed good salivary excretion with strong correlation coefficient between saliva and plasma concentrations up to median *T*~max~ values of plasma profiles as shown in [Figure 1](#f0005){ref-type="fig"}, [Figure 2](#f0010){ref-type="fig"}, [Figure 3](#f0015){ref-type="fig"}, [Figure 4](#f0020){ref-type="fig"}. Assuming one compartment linear model, salivary excretion rate is dependent on plasma drug concentration. This explains the close behavior of the saliva and plasma profiles. Dimensional analysis of all drugs under review is summarized in [Table 2](#t0010){ref-type="table"}. AUC*~t~*^∗^ and *C*~max~^∗^ values were in close agreement with *C*^∗^ values. This means that when *C*^∗^ is less than unity, AUC*~t~*^∗^ and *C*~max~^∗^ are also less than unity as in tolterodine, metformin and rosuvastatin. On the other hand such parameters are more than unity in paracetamol.Figure 1Paracetamol plasma and saliva mean profiles & correlations.Figure 2Metformin plasma and saliva mean profiles & correlations.Figure 3Tolterodine plasma and saliva mean profiles & correlations.Figure 4Rosuvastatin plasma and saliva mean profiles & correlations.Table 2Saliva/plasma dimensional analysis.ParameterTolterodineParacetamolMetforminRosuvastatinAUC^∗^0.421.360.270.17*C*~max~^∗^0.341.140.380.35*T*~max~^∗^2.371.471.291.47*C*^∗^0.341.460.390.18*P*~eff~^∗^248.391111.721.79890.7

However, *T*~max~^∗^ values were more than unity, suggesting a lag time between plasma and saliva compartments due to drug distribution/redistribution processes in the body.

On the other hand, intra/inter subject variability values for primary pharmacokinetic parameters in saliva matrix were close to or more than plasma matrix as shown in [Table 3](#t0015){ref-type="table"} and [Table 4](#t0020){ref-type="table"}. The optimum sample size, as calculated by Study Result program V1, showed that more subjects are needed in pivotal studies using saliva matrix as compared to plasma matrix to demonstrate bioequivalence with adequate power of more than 80%.Table 3BA/BE metrics and statistics in saliva matrix.Tolterodine[a](#tblfn1){ref-type="table-fn"}MetforminParacetamolRosuvastatinAUC*~t~* 90%\
C.I. (CV%)1199 pg·h/ml\
(82)61.8--126.6\
(47.4)85.2--120.3\
(29.9)57.7--115.9\
(47.2)*C*~max~ 90%\
C.I. (CV%)338 pg/ml\
(70)64.1--109.8\
(57.6)78.3--135.1\
(46.8)61.3--124.8\
(48.0)Optimum *N*55664850[^1]Table 4BA/BE metrics and statistics in plasma matrix.Tolterodine[a](#tblfn2){ref-type="table-fn"}MetforminParacetamolRosuvastatinAUC*~t~* 90%\
C.I. (CV%)3152 pg·h/ml\
(77)68.8--134.9\
(48.6)96.8--109.1\
(10.2)72.7--111.4\
(28.8)*C*~max~ 90%\
C.I. (CV%)1237 pg/ml\
(77)69.8--125.1\
(38.6)86.8--116.5\
(25.2)76.3--151.6\
(46.4)Optimum *N*48542448[^2]

This explains why 90% confidence intervals shown in [Table 3](#t0015){ref-type="table"} and [Table 4](#t0020){ref-type="table"} did not fall within 80--125% acceptance range, for all parameters with high variability values in such pilot studies. Pilot studies are not meant to show bioequivalence, but rather to compare saliva versus plasma matrices. Pivotal studies are needed to be done in future to show bioequivalence in both saliva and plasma matrices.

Mean concentration profiles of the reference product were used to estimate the effective intestinal permeability values in plasma and saliva. [Fig. 3](#f0015){ref-type="fig"} shows observed versus SimCYP-predicted concentration profiles with correlation coefficients of 0.88 indicating good fitting of observed concentrations. Optimized effective permeability coefficients were 10.74 × 10^−4^ cm/s, with Fa = 1. This confirms our previous finding that effective permeability and protein binding are major key factors in salivary excretion and our previous assumption that intestinal permeability is similar to salivary mucosal permeability ([@b0020]).

From regulatory point of view, the US FDA guidance for industry stated "The statutory definitions of BA and BE, expressed in terms of rate and extent of absorption of the active ingredient or moiety to the site of action, emphasize the use of pharmacokinetic measures in an accessible biological matrix such as blood, plasma, and/or serum to indicate release of the drug substance from the drug product into the systemic circulation" ([@b0010]).

Hence, from the data collected for drugs in SECS classes I, II and III there is a high potential in BA/BE studies for saliva to be considered as a surrogate for plasma concentration. This line of research can help validate the newly proposed salivary excretion classification system. The use of saliva instead of plasma in such studies makes them non-invasive, easy and with lower clinical cost, less clinical staff and less clinical burden.

More research studies of candidate drugs that fall into classes I, II and III will be done in order to compare saliva versus plasma bioavailability and bioequivalence; and demonstrate SECS robustness.
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[^1]: BA values represent calculated AUC*~t~* and *C*~max~ with inter subject CV%. Optimum *N* was calculated assuming intra subject CV is half inter subject CV%.

[^2]: BA values represent calculated AUC*~t~* and *C*~max~ with inter subject CV%. Optimum *N* was calculated assuming intra subject CV is half inter subject CV%.
